Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome

Janiga, Jenna; Kentley, Jonathan; Nabhan, Chadi; Abdulla, Farah

doi:10.1080/10428194.2017.1347650

Cited by 15 publications

(16 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gemcitabine is a pyrimidine analog that has been reported to have an ORR of 62.5–75% and a CRR of 22% in stage IB–IVB CTCL . In our experience, gemcitabine is well tolerated and can lead to rapid control of widespread tumours before transitioning to other therapy such as interferon.…”

Section: Systemic Therapiesmentioning

confidence: 78%

“…Patient's blood is centrifuged in order to isolate the leucocyte compartment, incubated with 8‐MOP, irradiated with UVA, and subsequently returned to the patient. This leukapheresis, in which approximately 5% of the patient's isolated cells are treated, results in apoptosis of malignant cells and expansion of dendritic cells, resulting in an overall enhanced Th1 response …”

Section: Systemic Therapiesmentioning

confidence: 99%

“…With the traditional dosing of 30 mg IV three times weekly during induction therapy and once per week for maintenance phase, adverse events of grade 3 or higher were observed in 62% of patients, with most serious complications being bacterial sepsis, fungal infections, viral reactivations and haematological toxicities . New low‐dose regimen of 10 mg three times weekly has shown comparable responses with much reduced risk of adverse events . Close monitoring and prophylactic antimicrobial cover are nevertheless recommended.…”

Section: Systemic Therapiesmentioning

confidence: 99%

“…Instead, alloSCT has been successfully reported in this context to achieve durable remission by exploiting the graft‐versus‐lymphoma effect . Factors that influence success include disease status, type of conditioning regimen and donor type . Overall survival of 46% and 44% at 5 and 7 years, respectively, after alloSCT has been observed .…”

Section: Systemic Therapiesmentioning

confidence: 99%

See 3 more Smart Citations

Management of cutaneous T‐cell lymphomas: Established and emergent therapies

et al. 2019

View full text Add to dashboard Cite

Cutaneous T-cell lymphoma is an uncommon group of non-Hodgkin's lymphoma primarily affecting the skin. It is comprised of a variety of entities with different clinical behaviours and prognosis. Mycosis fungoides is the commonest subtype, and S ezary syndrome is a much rarer form of cutaneous T-cell lymphoma. At this stage, control rather than cure is the goal of therapy, with particular emphasis placed on preserving quality of life. Our review of the efficacy, safety profile and accessibility of treatment modalities for mycosis fungoides/S ezary syndrome is a tailored guide for the clinician treating these rare conditions.

show abstract

Section: Systemic Therapiesmentioning

confidence: 78%

Section: Systemic Therapiesmentioning

confidence: 99%

Section: Systemic Therapiesmentioning

confidence: 99%

Section: Systemic Therapiesmentioning

confidence: 99%

See 2 more Smart Citations

Management of cutaneous T‐cell lymphomas: Established and emergent therapies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Indeed, the overall response rates to single agent systemic therapies (such as the retinoid bexarotene or HDACi) range between 20% and 45% and relapses are common. 166,167 The MYC oncogene is often amplified in CTCL condition, and the capability of BETi to repress its expression has been widely discussed in literature, in particular for AML, MM, and Burkitt's lymphoma. [168][169][170][171] BCL2i is approved for relapsed or refractory chronic lymphocytic leukemia (CLL) with 17p deletion,.…”

mentioning

confidence: 99%

Epigenetic polypharmacology: A new frontier for epi‐drug discovery

Tomaselli

Lucidi

Rotili

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Recently, despite the great success achieved by the so‐called “magic bullets” in the treatment of different diseases through a marked and specific interaction with the target of interest, the pharmacological research is moving toward the development of “molecular network active compounds,” embracing the related polypharmacology approach. This strategy was born to overcome the main limitations of the single target therapy leading to a superior therapeutic effect, a decrease of adverse reactions, and a reduction of potential mechanism(s) of drug resistance caused by robustness and redundancy of biological pathways. It has become clear that multifactorial diseases such as cancer, neurological, and inflammatory disorders, may require more complex therapeutic approaches hitting a certain biological system as a whole. Concerning epigenetics, the goal of the multi‐epi‐target approach consists in the development of small molecules able to simultaneously and (often) reversibly bind different specific epi‐targets. To date, two dual histone deacetylase/kinase inhibitors (CUDC‐101 and CUDC‐907) are in an advanced stage of clinical trials. In the last years, the growing interest in polypharmacology encouraged the publication of high‐quality reviews on combination therapy and hybrid molecules. Hence, to update the state‐of‐the‐art of these therapeutic approaches avoiding redundancy, herein we focused only on multiple medication therapies and multitargeting compounds exploiting epigenetic plus nonepigenetic drugs reported in the literature in 2018. In addition, all the multi‐epi‐target inhibitors known in literature so far, hitting two or more epigenetic targets, have been included.

show abstract